Effects of chronic sildenafil use on pulmonary hemodynamics and clinical outcomes in heart transplantation.
This retrospective study originating from the Laval group demonstrated that peri-heart transplant sildenafil therapy was well tolerated and decreased MPAP, PVR, and TPG in patients with fixed secondary pulmonary hypertension in the absence of ventricular assist device support. Excellent early and late survival comparable to patients without significant pulmonary hypertension was demonstrated. Duration of therapy was 163±116 days before heart transplant . Sildenafil was reintroduced early after transplant.